Results 211 to 220 of about 2,022,996 (246)

Inferring translational efficiency from transcriptomes improves noncanonical neoantigen prioritization and cancer patient stratification. [PDF]

NPJ Precis Oncol
Ma Y, Gao C, Xu K, Wang K, Ma J, Cai Y, Lv D, Li S, Jiang Q, Wang K, Li Y, Xu J.   +11 more
europepmc   +1 more source

Microsatellite Phenotype as a Guide for Immunotherapy in Colorectal Cancer: Current Status and Future Perspectives. [PDF]

Genes (Basel)
Koustas E, Trifylli EM, Oraiopoulos V, Karamouzis MV, Sarantis P.   +4 more
europepmc   +1 more source

Proteomic and proteogenomic identification of targetable T-cell antigens in multiple myeloma. [PDF]

Blood Adv
Zuleger G, de Andrade Krätzig N, Giansanti P, Darzentas N, Barresi M, Teske A, Trozzo R, Lutzenberger S, Forster S, Descoeudres A, Wagner A, Meyer HS, Hammel M, Lee CY, Hiltensperger M, Busch DH, Meyer B, Canzar S, Hecker JS, Brüggemann M, Rad R, Bräunlein E, Krackhardt AM.   +22 more
europepmc   +1 more source

Bidirectional Interplay Between Tumor Vaccines and the Tumor Microenvironment: Mechanisms, Cold-to-Hot Conversion, and Combination Strategies. [PDF]

Vaccines (Basel)
Shen Z, Feng Q, Wang F, Luo H.
europepmc   +1 more source

The immunogenicity control axis: a multi-omics framework for integrating epigenetic, DNA damage response, and immune states in cancer. [PDF]

Front Genet
Srivastava M, Singh S, Ameta D, Singh A, Banerjee M, Kushwah AS.   +5 more
europepmc   +1 more source

Tumor Mutational Burden Predicts Neoantigen Profiles and Immunotherapy Response in Microsatellite Stable Tumors Across Different Cancer Types

Frontiers in Immunology
Introduction Immunotherapy has shown positive response in many patients with microsatellite instable (MSI-H) tumors, but its effectiveness in microsatellite stable (MSS) tumors remains limited. We hypothesize that tumor mutational burden (TMB) can help identify a biologically distinct subset of MSS tumors that ...
Inti Zlobec, Maria Anisimova, Tugçe Bilgin Sonay   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Mutation burden and tumor neoantigens in RCC patients (pts) treated with nivolumab.

Journal of Clinical Oncology, 2016
514 Background: Durable benefit with CTLA4 or PD1 blockade associates with high somatic mutation burden in melanoma and lung cancer (Snyder, NEJM 2014; Rizvi, Science 2015). The same studies suggest that tumor neoantigens arising from somatic mutations may be mediating this association.
Martin Henner Voss, Matthew David Hellmann, Yingbei Chen, Theresa Margaret Gold, Courtney Rose Lambert, Eliezer VanAllen, Toni K. Choueiri, Alexandra Snyder Charen, Robert J. Motzer   +8 more
openaire   +1 more source

A study of tumor neoantigen burden and HLA-LOH by whole-exome sequencing to characterize immune biomarkers of lung cancer.

Journal of Clinical Oncology, 2023
8527 Background: Lung cancer is a leading cause of cancer-related death worldwide. Precision immunotherapy, such as the use of immune checkpoint inhibitors (ICIs), has been shown to improve the survival of lung cancer patients. Cancer cells with high amount of neoantigens are more likely to be captured by immune cells and thus patients with high ...
Wei Wang, Wenting Liao, Baoling Zhen, Tianrong Ji, Chen Du, Shaochen Cheng, Yaru Chen, Jie Yang   +7 more
openaire   +1 more source